Soluble CD105 is prognostic of disease recurrence in prostate cancer patients

in Endocrine-Related Cancer

Correspondence should be addressed to N A Bhowmick: bhowmickn@cshs.org
Restricted access

While the overall 5-year survival rate for prostate cancer is near 100%, up to 35% of patients will develop recurrent disease. At the time of prostatectomy, prostate-specific antigen (PSA) is used to guide primary therapy with the goal of curative intervention. It can be valuable to know when primary therapy may not in fact be curative, so that subsequent adjuvant therapy can be administered at an early stage to limit progression. We examined prostate cancer patients with PSA ≤10 ng/mL that were all subjected to prostatectomy with at least 5 years of follow-up (n = 181). Based on data that endoglin (CD105) signaling in the tumor can contribute to prostate cancer progression, we examined the expression of soluble CD105 (sCD105) in the patient plasma. To determine the relation of plasma sCD105 measures to cellular CD105 in tissues, we tested an independent set of prostate cancer tissues and paired plasma (n = 31). Elevated sCD105 was found to be associated with recurrence-free survival of prostate cancer patients. Further, sCD105 levels in patient plasma were inversely correlated with cellular CD105 expression. This translational study supported preclinical data demonstrating the pro-tumorigenic capacity of cellular CD105 and provide a blood-based biomarker, sCD105, for prostate cancer recurrence in prostatectomy patients with PSA levels ≤10 ng/mL.

 

      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 449 449 287
Full Text Views 40 40 24
PDF Downloads 19 19 11
  • AllmerCSargentDJ 2000 . In SAS User's Group International Proceedings (SUGI28) paper 20128. (available at: https://support.sas.com/resources/papers/proceedings/proceedings/sugi28/201-28.pdf)

    • Search Google Scholar
    • Export Citation
  • BollaMvan PoppelHColletteLvan CanghPVekemansKDa PozzoLde ReijkeTMVerbaeysABossetJFvan VelthovenR 2005 Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 572578. (https://doi.org/10.1016/S0140-6736(05)67101-2)

    • Search Google Scholar
    • Export Citation
  • BollaMvan PoppelHTombalBVekemansKDa PozzoLde ReijkeTMVerbaeysABossetJFvan VelthovenRColombelM 2012 Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 20182027. (https://doi.org/10.1016/S0140-6736(12)61253-7)

    • Search Google Scholar
    • Export Citation
  • CoxD 1986 Citation-classic – regression-models and life-tables. Current Contents/Agriculture Biology and Environmental Sciences 42 16.

    • Search Google Scholar
    • Export Citation
  • DalesJPGarciaSBonnierPDuffaudFAndrac-MeyerLRamuzOLavautMNAllasiaCCharpinC 2003 CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlations between immunohistochemical analysis and long-term follow-up in a series of 929 patients. American Journal of Clinical Pathology 374380. (https://doi.org/10.1309/1kf54l6rb625556w)

    • Search Google Scholar
    • Export Citation
  • ErdemOTaskiranCOnanMAErdemMGunerHAtaogluO 2006 CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecologic Oncology 10071011. (https://doi.org/10.1016/j.ygyno.2006.06.010)

    • Search Google Scholar
    • Export Citation
  • FaisalFATosoianJJHanMMacuraKJPavlovichCPLotanTL 2019 MP09-05 clinical, pathologic, and oncologic findings of radical prostatectomy patients with extraprostatic extension diagnosed on pre-operative prostate biopsy. Journal of Urology 201 e108e109. (https://doi.org/10.1097/01.JU.0000555129.46273.1b)

    • Search Google Scholar
    • Export Citation
  • FonsattiEAltomonteMNicotraMRNataliPGMaioM 2003 Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 65576563. (https://doi.org/10.1038/sj.onc.1206813)

    • Search Google Scholar
    • Export Citation
  • FreedlandSJHumphreysEBMangoldLAEisenbergerMDoreyFJWalshPCPartinAW 2005 Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 433439. (https://doi.org/10.1001/jama.294.4.433)

    • Search Google Scholar
    • Export Citation
  • FujitaKEwingCMChanDYMangoldLAPartinAWIsaacsWBPavlovichCP 2009 Endoglin (CD105) as a urinary and serum marker of prostate cancer. International Journal of Cancer 664669. (https://doi.org/10.1002/ijc.24007)

    • Search Google Scholar
    • Export Citation
  • GandagliaGBrigantiAClarkeNKarnesRJGraefenMOstPZietmanALRoachM3rd 2017 Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. European Urology 689709. (https://doi.org/10.1016/j.eururo.2017.01.039)

    • Search Google Scholar
    • Export Citation
  • GrambschPMTherneauTM 1994 Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 515526. (https://doi.org/10.1093/biomet/81.3.515)

    • Search Google Scholar
    • Export Citation
  • KapurNKMorineKJLetarteM 2013 Endoglin: a critical mediator of cardiovascular health. Vascular Health and Risk Management 195206. (https://doi.org/10.2147/VHRM.S29144)

    • Search Google Scholar
    • Export Citation
  • KatoMPlacencio-HickokVRMadhavAHaldarSTripathiMBilletSMishraRSmithBRohena-RiveraKAgarwalP 2019 Heterogeneous cancer-associated fibroblast population potentiates neuroendocrine differentiation and castrate resistance in a CD105-dependent manner. Oncogene 716730. (https://doi.org/10.1038/s41388-018-0461-3)

    • Search Google Scholar
    • Export Citation
  • KumarSGhellalALiCByrneGHaboubiNWangJMBundredN 1999 Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Research 856861.

    • Search Google Scholar
    • Export Citation
  • LiCGuoBWilsonPBStewartAByrneGBundredNKumarS 2000 Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. International Journal of Cancer 122126. (https://doi.org/10.1002/(sici)1097-0215(20000320)89:2<122::aid-ijc4>3.0.co;2-m)

    • Search Google Scholar
    • Export Citation
  • LiuYJovanovicBPinsMLeeCBerganRC 2002 Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 82728281. (https://doi.org/10.1038/sj.onc.1206117)

    • Search Google Scholar
    • Export Citation
  • MadhavAAndresADuongFMishraRHaldarSLiuZAngaraBGottliebRZumstegZSBhowmickNA 2018 Antagonizing CD105 enhances radiation sensitivity in prostate cancer. Oncogene 43854397. (https://doi.org/10.1038/s41388-018-0278-0)

    • Search Google Scholar
    • Export Citation
  • NikueiPRajaeiMMalekzadehKNejatizadehAMohseniFAtashAbParvarA 2017 Accuracy of soluble endoglin for diagnosis of preeclampsia and its severity. Iranian Biomedical Journal 312330. (https://doi.org/10.18869/acadpub.ibj.21.5.312)

    • Search Google Scholar
    • Export Citation
  • PaauweMSchoonderwoerdMJAHeldermanRFCPHarryvanTJGroenewoudAvan PeltGWBorRHemmerDMVersteegHHSnaar-JagalskaBE 2018 Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis. Clinical Cancer Research 63316344. (https://doi.org/10.1158/1078-0432.CCR-18-0329)

    • Search Google Scholar
    • Export Citation
  • PrensnerJRRubinMAWeiJTChinnaiyanAM 2012 Beyond PSA: the next generation of prostate cancer biomarkers. Science Translational Medicine 127rv3. (https://doi.org/10.1126/scitranslmed.3003180)

    • Search Google Scholar
    • Export Citation
  • SaadRSEl-GoharyYMemariELiuYLSilvermanJF 2005 Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Human Pathology 955961. (https://doi.org/10.1016/j.humpath.2005.06.019)

    • Search Google Scholar
    • Export Citation
  • SchemperMSmithTL 1996 A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 343346. (https://doi.org/10.1016/0197-2456(96)00075-x)

    • Search Google Scholar
    • Export Citation
  • SchmidtC 2017 Reconsidering prostate cancer screening. Journal of the National Cancer Institute 12. (https://doi.org/10.1093/jnci/djw337)

    • Search Google Scholar
    • Export Citation
  • SharmaNSeftorRESeftorEAGrumanLMHeidgerPMJrCohenMBLubaroffDMHendrixMJ 2002 Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 189201. (https://doi.org/10.1002/pros.10048)

    • Search Google Scholar
    • Export Citation
  • SiegelRLMillerKDJemalA 2017 Cancer statistics, 2017. CA: A Cancer Journal for Clinicians 730. (https://doi.org/10.3322/caac.21387)

  • SvatekRSKaramJARoehrbornCGKarakiewiczPISlawinKMShariatSF 2008 Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clinical Cancer Research 33623366. (https://doi.org/10.1158/1078-0432.CCR-07-4707)

    • Search Google Scholar
    • Export Citation
  • TakahashiNKawanishi-TabataRHabaATabataMHarutaYTsaiHSeonBK 2001 Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clinical Cancer Research 524532.

    • Search Google Scholar
    • Export Citation
  • TanakaFOtakeYYanagiharaKKawanoYMiyaharaRLiMYamadaTHanaokaNInuiKWadaH 2001 Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clinical Cancer Research 34103415.

    • Search Google Scholar
    • Export Citation
  • TaskiranCErdemOOnanAArisoyOAcarAVuralCErdemMAtaogluOGunerH 2006 The prognostic value of endoglin (CD105) expression in ovarian carcinoma. International Journal of Gynecological Cancer 17891793. (https://doi.org/10.1111/j.1525-1438.2006.00658.x)

    • Search Google Scholar
    • Export Citation
  • TeradaNAkamatsuSKobayashiTInoueTOgawaOAntonarakisES 2017 Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology 565573. (https://doi.org/10.1177/1758834017719215)

    • Search Google Scholar
    • Export Citation
  • WikstromPLissbrantIFStattinPEgevadLBerghA 2002 Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 268275. (https://doi.org/10.1002/pros.10083)

    • Search Google Scholar
    • Export Citation
  • YouSKnudsenBSErhoNAlshalalfaMTakharMAl-Deen AshabHDavicioniEKarnesRJKleinEADenRB 2016 Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Research 49484958. (https://doi.org/10.1158/0008-5472.CAN-16-0902)

    • Search Google Scholar
    • Export Citation
  • ZhaoSGChangSLErhoNYuMLehrerJAlshalalfaMSpeersCCooperbergMRKimWRyanCJ 2017 Associations of luminal and basal subtyping of prostate cancer With prognosis and response to androgen deprivation therapy. JAMA Oncology 16631672. (https://doi.org/10.1001/jamaoncol.2017.0751)

    • Search Google Scholar
    • Export Citation